FMR LLC and Abigail P. Johnson filed Amendment No. 5 to their Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of common stock in Viking Therapeutics Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC and Abigail P. Johnson each reported beneficial ownership of 9,539,067.32 shares of Viking Therapeutics common stock.
  • Percent of class: The reported holdings represent 7.7% of the outstanding common stock of Viking Therapeutics Inc.
  • Sole voting power: FMR LLC reported sole voting power over 9,503,286.42 shares; Abigail P. Johnson reported sole voting power over 0.00 shares.
  • Sole dispositive power: Both FMR LLC and Abigail P. Johnson each reported sole dispositive power over 9,539,067.32 shares.
  • Shared voting and dispositive power: Both reporting persons disclosed 0.00 shares subject to shared voting or shared dispositive power.
  • Event date: The date of the event requiring this filing was September 30, 2026.

FMR LLC and Abigail P. Johnson Disclose Position in Viking Therapeutics as of September 30, 2026

According to the filing, FMR LLC, a Delaware-organized holding company, and Abigail P. Johnson, a U.S. citizen, jointly submitted Amendment No. 5 to their Schedule 13G disclosing their respective beneficial ownership positions in Viking Therapeutics Inc. (NASDAQ:VKTX), whose common stock carries CUSIP number 92686J106. The filing was signed on November 4, 2026, by Stephanie J. Brown, acting under powers of attorney granted on behalf of both FMR LLC and Abigail P. Johnson.

The filing reports that FMR LLC holds sole voting power over 9,503,286.42 shares and sole dispositive power over 9,539,067.32 shares. Abigail P. Johnson is reported as holding sole dispositive power over the same 9,539,067.32 shares, with zero sole or shared voting power. Neither reporting person disclosed any shared voting or shared dispositive power. The aggregate beneficial ownership reported by each person is 9,539,067.32 shares, equating to 7.7% of the class, according to the filing.

The filing also discloses, under Item 6, that "one or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of VIKING THERAPEUTICS INC," but states that "no one other person's interest in the COMMON STOCK of VIKING THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK." The filers certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

FMR LLC and Abigail P. Johnson filed Amendment No. 5 to their Schedule 13G reporting aggregate beneficial ownership of 9,539,067.32 shares, or 7.7%, of Viking Therapeutics Inc. common stock as of September 30, 2026.